Current Concepts in the Pathogenesis of Age-Related Macular Degeneration

Archives of Ophthalmology

Volumn 122, Issue 4, 2004, Pages 598-614

  Zarbin, Marco A ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; BRUCH MEMBRANE; CHOROID; CHOROID CAPILLARY LAYER; CHRONIC INFLAMMATION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA INJURY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

AGING; BRUCH MEMBRANE; CHOROIDAL NEOVASCULARIZATION; EXTRACELLULAR MATRIX; HUMANS; MACULAR DEGENERATION; OXIDATIVE STRESS; PIGMENT EPITHELIUM OF EYE;

EID: 1842478123     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.4.598     Document Type: Review

References (270)

1. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104:7-21.
2. Gass JDM. Stereoscopic Atlas of Macular Diseases: Diagnosis and Management. 4th ed. St Louis, Mo: Mosby-Year Book Inc, 1997:70-105.
3. Guyer DR, Fine SL, Maguire MG, Hawkins BS, Owens SL, Murphy RP. Subfoveal choroidal neovascular membranes in age-related macular degeneration: visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol. 1986;104:702-705.
4. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol. 2002;133:168-169.
5. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
6. Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1993;100:406-414.
7. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-210.
8. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol. 1996;80:9-14.
9. Harman D. Ageing: a theory based on free radical and radiation chemistry. J Gerontol. 1956;11:298-300.
10. Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283:1482-1488.
11. Verzar F. Aging of connective tissue. Gerontologia. 1957;1:363-378.
12. Robert L. Mechanisms of aging of the extracellular matrix: role of the elastin-laminin receptor. Gerontology. 1998;44:307-317.
13. Chandrasekhar S, Sorrentino JA, Millis AJ. Interaction of fibronectin with collagen: age-specific defect in the biological activity of human fibroblast fibronectin. Proc Natl Acad Sci U S A. 1983;80:4747-4751.
14. Murano S, Thweatt R, Shmookler-Reis RJ, Jones RA, Moerman EJ, Goldstein S. Diverse gene sequences are overexpressed in Werner syndrome fibroblasts undergoing premature replicative senescence. Mol Cell Biol. 1991;11:3905-3914.
15. Hu O, Moerman EJ, Goldstein S. Altered expression and regulation of the α5β1 integrin-fibronectin receptor lead to reduced amounts of functional α5β1 heterodimer on the plasma membrane of senescent human diploid fibroblasts. Exp Cell Res. 1996;224:251-263.
16. Rasoamanantena P, Thweatt R, Labat-Robert J, Goldstein S. Altered regulation of fibronectin gene expression in Werner syndrome fibroblasts. Exp Cell Res. 1994;213:121-127.
17. Yu CE, Oshima J, Wijsman EM, et al. Mutations in the consensus helicase domains of the Werner syndrome gene: Werner's Syndrome Collaborative Group. Am J Hum Genet. 1997;60:330-341.
18. Maillard LC. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Hebd Seances Acad Sci. 1912;154:66-68.
19. Feeney-Burns L, Hilderbrand ES, Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci. 1984;25:195-200.
20. Sundelin SP, Wihlmark U, Nilsson SEG, Brunk UT. Lipofuscin accumulation in cultured retinal pigment epithelial cells reduces their phagocytic capacity. Curr Eye Res. 1998;17:851-857.
21. Kennedy CJ, Rakoczy PE, Constable IJ. Lipofuscin of the retinal pigment epithelium: a review. Eye. 1995;9(pt 6):763-771.
22. Okubo A, Rosa RH Jr, Bunce CV, et al. The relationship of age changes in retinal pigment epithelium and Bruch's membrane. Invest Ophthalmol Vis Sci. 1999;40:443-449.
23. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PGH, de Jong PTVM. Morphometric analysis of Bruch's membrane, the choriocapillaris and the choroid in ageing. Invest Ophthalmol Vis Sci. 1994;35:2857-2864.
24. Newsome DA, Huh W, Green WR. Bruch's membrane age-related changes vary by region. Curr Eye Res. 1987;6:1211-1221.
25. Farkas TG, Sylvester V, Archer D, Altona M. The histochemistry of drusen. Am J Ophthalmol. 1971;71:1206-1215.
26. Sarks SH. Aging and degeneration in the macular region: a clinicopathologic study. Br J Ophthalmol. 1976;60:324-341.
27. Burns RP, Feeney-Burns L. Clinicomorphologic correlations of drusen and Bruch's membrane. Trans Am Ophthalmol Soc. 1980;78:206-223.
28. Ruiz A, Brett P, Bok D. TIMP-3 is expressed in the human retinal pigment epithelium. Biochem Biophys Res Commun. 1996;226:467-474.
29. Alexander JP, Bradley JMB, Gabourel JC, Acott TS. Expression of matrix metalloproteinases and inhibitors by human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1990;31:2520-2528.
30. Leu ST, Batni S, Radeke MJ, Johnson LV, Anderson DH, Clegg DO. Drusen are cold spots for proteolysis: expression of matrix metalloproteinases and their tissue inhibitor proteins in age-related macular degeneration. Exp Eye Res. 2002;74:141-154.
31. Guo L, Hussain AA, Limb GA, Marshall J. Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. Invest Ophthalmol Vis Sci. 1999;40:2676-2682.
32. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP-3) in patients with Sorsby's fundus dystrophy. Nat Genet. 1994;8:352-356.
33. Langton KP, Barker MD, McKie N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation. J Biol Chem. 1998;273:16778-16781.
34. Kamei M, Hollyfield JG. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:2367-2375.
35. Bailey TA, Alexander RA, Dubovy SR, Luthert PJ, Chong NHV. Measurement of TIMP-3 expression and Bruch's membrane thickness in human macula. Exp Eye Res. 2001;73:851-858.
36. Jacobson SG, Cideciyan AV, Regunath G, et al. Night blindness in Sorsby's fundus dystrophy reversed by vitamin A. Nat Genet. 1995;11:27-32.
37. Das A, Frank RN, Zhang NL, Turezyn TJ. Ultrastructural localization of extracellular matrix components in human retinal vessels and Bruch's membrane. Arch Ophthalmol. 1990;108:421-429.
38. Hewitt AT, Nakazawa K, Newsome DA. Analysis of newly synthesized Bruch's membrane proteoglycans. Invest Ophthalmol Vis Sci. 1989;30:478-486.
39. Marshall J, Hussain AA, Starita C, Moore DJ, Patmore AL. Aging and Bruch's membrane. In: Marmor MF, Wolfensberger TJ, eds. The Retinal Pigment Epithelium. New York, NY: Oxford University Press; 1998:669-692.
40. Hogan MJ, Alvarado J. Studies on the human macula, IV:aging changes in Bruch's membrane. Arch Ophthalmol. 1967;77:410-420.
41. Starita C, Hussain AA, Pagliarini S, Marshall J. Hydrodynamics of ageing Bruch's membrane: implications for macular disease. Exp Eye Res. 1996;62:565-572.
42. Starita C, Hussain AA, Patmore A, Marshall J. Localization of the site of major resistance to fluid transport in Bruch's membrane. Invest Ophthalmol Vis Sci. 1997;38:762-767.
43. Karwatowski WS, Jeffries TE, Duance VC, Albon J, Bailey AJ, Easty DL. Preparation of Bruch's membrane and analysis of the age-related changes in the structural collagens. Br J Ophthalmol. 1995;79:944-952.
44. Green WR, Enger C. Age-related macular degeneration histopathologic studies: the 1992 Lorenz E Zimmerman Lecture. Ophthalmology. 1993;100:1519-1535.
45. Loeffler KU, Lee WR. Is basal laminar deposit unique for age-related macular degeneration? Arch Ophthalmol. 1992;110:15-16.
46. Loeffler KU, Lee WR. Basal linear deposit in the human macula. Graefes Arch Clin Exp Ophthalmol. 1986;224:493-501.
47. Pauleikhoff P, Wojtecki S, Muller D, Boulton S, Boulton M, Heiligenhaus A. Adhesion molecules and lipid accumulation in Bruch's membrane with age. Invest Ophthalmol Vis Sci. 1999;40:S920.
48. Curcio CA, Millican CL. Basal linear deposit and large drusen are specific for early age-related maculopathy. Arch Ophthalmol. 1999;117:329-339.
49. Handa JT, Verzijl N, Matsunaga H, et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Invest Ophthalmol Vis Sci. 1999;40:775-779.
50. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99-111.
51. King G, Brownlee M. The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am. 1996;25:255-270.
52. Lyda W, Eriksen N, Krishna N. Studies of Bruch's membrane: flow and permeability studies in a Bruch's membrane-choroid preparation. Am J Ophthalmol. 1957;44:362-370.
53. Moore DJ, Hussain AA, Marshall J. Age-related variation in the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci. 1995;36:1290-1297.
54. Holz FG, Sheraidah G, Pauleilkhoff D, Bird AC. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol. 1994;112:402-406.
55. Sheraidah G, Steinmetz R, Maguire J, Pauleikhoff D, Marshall J, Bird AC. Correlation between lipids extracted from Bruch's membrane and age. Ophthalmology. 1993;100:47-51.
56. Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D. Characterization of peroxidized lipids in Bruch's membrane. Retina. 1999;19:141-147.
57. Hogan MJ, Alvarado JA, Weddell JE. Histology of the Human Eye: An Atlas and Textbook. Philadelphia, Pa: WB Saunders Co; 1971.
58. Pauleikhoff D, Chen JC, Chisholm IH, Bird AC. Choroidal perfusion abnormality with age-related Bruch's membrane change. Am J Ophthalmol. 1990;109:211-217.
59. Moore DJ, Clover GM. The effect of age on the macromolecular permeability of human Bruch's membrane. Invest Ophthalmol Vis Sci. 2001;42:2970-2975.
60. Hussain AA, Rowe L, Marshall J. Age-related alterations in the diffusional transport of amino acids across the human Bruch's-choroid complex. J Opt Soc Am A Opt Image Sci Vis. 2002;19:166-172.
61. Pauleikhoff D, Sheraidah G, Marshall J, Bird AC, Wessing A. Biochemical and histochemical analysis of age related lipid deposits in Bruch's membrane. Ophthalmologe. 1994;91:730-734.
62. Lutty G, Grunwald J, Majji AB, Uyama M, Yoneya S. Changes in choriocapillaris and retinal pigment epithelium (RPE) in age-related macular degeneration. Mol Vis. 1999;5:35-38.
63. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane: a histochemical and morphologic study. Ophthalmology. 1990;97:171-178.
64. Grunwald J, Hariprasad S, Dupont J. Effect of aging on foveolar choroidal circulation. Arch Ophthalmol. 1998;116:150-154.
65. Guymer R, Luthert P, Bird A. Changes in Bruch's membrane and related structures with age. Prog Retin Eye Res. 1999;18:59-90.
66. Korte GE, Burns MS, Bellhorn RW. Epithelium-capillary interactions in the eye: the retinal pigment epithelium and the choriocapillaris. Int Rev Cytol. 1989;114:221-248.
67. Wallace DC, Brown MD, Melov S, Graham B, Lott M. Mitochondrial biology, degenerative diseases and aging. Biofactors. 1998;7:187-190.
68. Samiec PS, Drews-Botsch C, Flagg EW, et al. Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. Free Radic Biol Med. 1998;24:699-704.
69. Rikans LE, Moore DR. Effect of aging on aqueous-phase antioxidants in tissues of male Fischer rats. Biochim Biophys Acta. 1988;966:269-275.
70. Vandewoude MFJ, Vandewoude MG. Vitamin E status in normal population: the influence of age. J Am Coll Nutr. 1987;6:307-311.
71. Coudray C, Roussel AM, Arnaud J, Favier A. Selenium and antioxidant vitamin and lipidoperoxidation levels in preaging French population: EVA Study Group. Biol Trace Elem Res. 1997;57:183-190.
72. Castorina C, Campisi A, Di Giacomo C, Sorrenti V, Russo A, Vanella A. Lipid peroxidation and antioxidant enzymatic systems in rat retina as a function of age. Neurochem Res. 1992;17:599-604.
73. Liles MR, Newsome DA, Oliver PD. Antioxidant enzymes in the aging human retinal pigment epithelium. Arch Ophthalmol. 1991;109:1285-1288.
74. Friedrichson T, Kalbach H, Buck P, van Kuijk F. Vitamin E in macular and peripheral tissues of the human eye. Curr Eye Res. 1995;14:693-701.
75. Beatty S, Koh H-H, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45:115-134.
76. Davies S, Mulroy L, McGarvery D, Truscott TG, Boulton M. The phototoxicity of lipofuscin. Invest Ophthalmol Vis Sci. 1998;39:S129.
77. Panda-Jonas S, Jonas J, Jakobczyk-Kmija M. Retinal pigment epithelial cell count distribution, and correlations in normal eyes. Am J Ophthalmol. 1996;121:181-189.
78. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32-46.
79. Cai J, Nelson KC, Wu M, Sternberg P, Jones DP. Oxidative damage and protection of the RPE. Prog Retin Eye Res. 2000;19:205-221.
80. De La Paz M, Anderson RE. Region and age-dependent variation in susceptibility of the human retinato lipid peroxidation. Invest Ophthalmol Vis Sci. 1992;33:3497-3499.
81. Boulton M, Donstov A, Jarvis-Evans J, Ostrovsky M, Svistunenko D. Lipofuscin is a photoinducible free radical generator. J Photochem Photobiol B. 1993;19:201-204.
82. Holz FG, Schutt F, Kopitz J, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci. 1999;40:737-743.
83. Wassell J, Davies S, Bardsley W, Boulton M. The photoreactivity of the retinal age pigment lipofuscin. J Biol Chem. 1999;274:23828-23832.
84. Katz ML, Christianson JS, Gao CL, Handlemen GL. Iron-induced fluorescence in the retina: dependence on vitamin A. Invest Ophthalmol Vis Sci. 1994;35:3613-3624.
85. Sakai N, Decatur J, Nakanishi K, Eldred G. Ocular age pigment "A2E": an unprecedented pyridinium bisretinoid. J Am Chem Soc. 1996;118:1559-1560.
86. Schutt F, Davies S, Kopitz J, Holz FG, Boulton ME. Photodamage to human RPE cells by A2-E, a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci. 2000;41:2303-2308.
87. Finnemann SC, Leung LW, Rodriguiez-Boulan E. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid bythe retinal pigment epithelium. Proc Natl Acad Sci USA. 2002;99:3842-3847.
88. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:14682-14687.
89. McLeod DS, Taomoto M, Otsuji T, Green WR, Sunness JS, Lutty GA. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002;43:1986-1993.
90. Age-Related Eye Disease Study Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and visual loss. Arch Ophthalmol. 2001;119:1417-1436.
91. Karcioglu ZA. Zinc in the eye. Surv Ophthalmol. 1982;27:114-122.
92. Eye Disease Case Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch Ophthalmol. 1993;111:104-109.
93. West S, Vitale S, Hallfrisch J, et al. Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol. 1994;112:222-227.
94. Vanden Langenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol. 1998;148:204-214.
95. Delcourt C, Cristol JP, Tessier F, Leger CL, Descomps B, Papoz L. Age-related macular degeneration and antioxidant status in the POLA study: POLA Study Group: Pathologies Oculaires Liees a l'Age. Arch Ophthalmol. 1999;117:1384-1390.
96. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration: Eye Disease Case-Control Study Group. JAMA. 1994;272:1413-1420
97. Smith W, Mitchell P, Webb K, Leeder SR. Dietary antioxidants and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 1999;106:761-767.
98. Hawkins BS, Bird A, Klein R, West SK. Epidemiology of age-related macular degeneration. Mol Vis. 1999;5:26-29.
99. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration. Ophthalmology. 1999;106:1049-1055.
100. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: a case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology. 2000;107:2224-2232.
101. Vingerling JR, Klaver CC, Hofman A, de Jong PT. Epidemiology of age-related maculopathy. Epidemiol Rev. 1995;17:347-360.
102. Wallace DC. Mitochondrial DNA in aging and disease. Sci Am. 1997;277:40-47.
103. Chow CK, Thacker RR, Changchit C, et al. Lower levels of vitamin C and carotenes in plasma of cigarette smokers. J Am Coll Nutr. 1986;5:305-312.
104. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect. 1985;64:111-126.
105. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology. 1999;106:1049-1055.
106. Klein R, Klein BE, Cruickshanks KJ. The prevalence of age-related maculopathy by geographic region and ethnicity. Prog Retin Eye Res. 1999;18:371-389.
107. Sundelin SP, Nilsson SEG, Brunk UT. Lipofuscin-formation in cultured retinal pigment epithelial cells is related to their melanin content. Free Radic Biol Med. 2001;30:74-81.
108. Weiter JJ, Delori FC, Wing GL, Fitch KA. Retinal pigment epithelial lipofuscin and melanin and choroidal melanin in human eyes. Invest Ophthalmol Vis Sci. 1986;27:145-152.
109. Gottsch JD, Pou S, Bynoe LA, Rosen GM. Hematogenous photosensitization: a mechanism for the development of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1990;31:1674-1682.
110. Torczynski E, Tso MOM. The architecture of the choriocapillaris at the posterior pole. Am J Ophthalmol. 1976;81:428-440.
111. Cai J, Wu M, Nelson K, Jones DP, Sternberg P Jr. Oxidant induced apoptosis in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40:959-966.
112. Frank RN, Amin RH, Puklin JE. Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Am J Ophthalmol. 1999;127:694-709.
113. Tate DJ Jr, Newsome DA, Oliver PD. Metallothionein shows an age-related decrease in human macular retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1993;34:2348-2351.
114. Cohen SM, Olin KL, Feuer WJ, Hjelmeland L, Keen CL, Morse LS. Low glutathione reductase and peroxidase activity in age-related macular degeneration. Br J Ophthalmol. 1994;78:791-794.
115. Oelcourt C, Cristol JP, Leger CL, Descomps B, Papoz L. Associations of antioxidant enzymes with cataract and age-related macular degeneration: The POLA Study: Pathologies Oculaires Liées à l'Age. Ophthalmology. 1999;106:215-222.
116. Packer L. Antioxidant action of carotenoids in vitro and in vivo and protection against oxidation of human low-density lipoproteins. Ann N Y Acad Sci. 1993;691:48-60.
117. Bohm F, Tinkler JH, Truscott TG. Carotenoids protect against cell membrane damage by the nitrogen dioxide radical. Nat Med. 1995;1:98-99.
118. Hammond BR Jr, Curran-Celentano J, Judd S, et al. Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns. Vision Res. 1996;36:2001-2012.
119. Hammond BR, Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Res. 1996;36:3003-3009.
120. Hammond BR Jr, Fuld K, Snodderly DM. Iris color and macular pigment optical density. Exp Eye Res. 1996;62:293-297.
121. Hammond BR Jr, Wooten BR, Snodderly DM. Density of the human crystalline lens is related to the macular pigment carotenoids, lutein and zeaxanthin. Optom Vis Sci. 1997;74:499-504.
122. Berendschot TTJM, Willemse-Assink JJM, Bastiaanse M, de Jong PTVM, van Norren D. Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci. 2002;43:1928-1932.
123. Landrum JT, Bone RA, Kilburn MD. The macular pigment: a possible role in protection from age-related macular degeneration. Adv Pharmacol. 1997;38:537-556.
124. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci. 2001;42:235-240.
125. Beatty S, Murray IJ, Henson DB, Carden D, Koh H-H, Boulton ME. Macular pigment and risk for age-related macular degeneration in subjects from a northern European population. Invest Ophthalmol Vis Sci. 2001;42:439-446.
126. Hernandez E, Sall J, Alexandridou A, Dix R, Csaky KG, Cousins SW. Polyunsaturated fat increases RPE susceptibility to lipid peroxidation: a mechanism for BLD formation? Invest Ophthalmol Vis Sci. 1999;40:S927.
127. Ishibashi T, Murata T, Hangai M, et al. Advanced glycation end products in age-related macular degeneration. Arch Ophthalmol. 1998;116:1629-1632.
128. Honda S, Farboud B, Hjelmeland LM, Handa JT. Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing advanced glycation end products in vitro. Invest Ophthalmol Vis Sci. 2001;42:2419-2425.
129. Hammes HP, Hoerauf H, Alt A, et al. N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE co-localize in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:1855-1859.
130. Delori FC, Fleckner MR, Goger DG, Weiter JJ, Dorey CK. Autofluorescence distribution associated with drusen in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:496-504.
131. Lois M, Owens SL, Coco R, Hopkins J, Fitzke FW, Bird AC. Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss. Am J Ophthalmol. 2002;133:341-349.
132. Green WR, Key S. Senile macular degeneration: a histopathologic study Trans Am Ophthalmol Soc. 1977;75:180-254.
133. Grindle CFJ, Marshall J. Ageing changes in Bruch's membrane and their functional implications. Trans Ophthalmol Soc U K. 1978;98:172-175.
134. Penfold P, Killingsworth M, Sarks S. An ultrastructural study of the role of leucocytes and fibroblasts in the breakdown of Bruch's membrane. Aust J Ophthalmol. 1984;12:23-31.
135. Penfold PL, Provis JM, Billson FA. Age-related macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1987;225:70-76.
136. Hageman GS, Luthert PJ, Chong VNH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
137. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age-related macular degeneration. Exp Eye Res. 2001;73:887-896.
138. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
139. Hageman G, Mullins R, Russell S, Johnson L, Anderson D. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J. 1999;13:477-484.
140. Johnson L, Ozaki S, Staples M, Erickson P, Anderson D. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70:441-449.
141. Mullins R, Anderson D, Russell S, Hageman G. Ocular drusen contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-846.
142. Sakaguchi H, Miyagi M, Shadrach KG, Rayborn ME, Crabb JW, Hollyfield JG. Clusterin is present in drusen in age-related macular degeneration. Exp Eye Res. 2002;74:547-549.
143. Ishibashi T, Patterson R, Ohnishi Y, Inomata H, Ryan SJ. Formation of drusen in the human eye. Am J Ophthalmol. 1986;101:342-353.
144. Feeney-Burns L, Ellersieck MR. Age-related changes in the ultrastructure of Bruch's membrane. Am J Ophthalmol. 1985;100:686-697.
145. Killingsworth MC. Age-related components of Bruch's membrane in the human eye. Graefes Arch Clin Exp Ophthalmol. 1987;225:406-412.
146. Mullins R, Aptsiauri N, Hageman G. Dendritic cells and proteins associated with immune-mediated processes are associated with drusen and may playa central role in drusen biogenesis. Invest Ophthalmol Vis Sci. 2000;41:S24.
147. Anderson DH, Ozaki S, Nealon M, et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol. 2001;131:767-781.
148. Penfold PL, Liew SC, Madigan MC, Provis JM. Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38:2125-2133.
149. Dastgheib K, Green W. Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch Ophthalmol. 1994;112:813-818.
150. Penfold P, Killingsworth M, Sarks S. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol. 1985;223:69-76.
151. Killingsworth M, Sarks J, Sarks S. Macrophages related to Bruch's membrane in age-related macular degeneration. Eye. 1990;4:613-621.
152. Seregard S, Algvere PV, Berglin L. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes. Graefes Arch Clin Exp Ophthalmol. 1994;232:325-329.
153. Hutchinson AK, Grossniklaus HE, Capone A. Giant-cell reaction in surgically excised subretinal neovascular membrane. Arch Ophthalmol. 1993;111:734-735.
154. Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci: 1999;40:1912-1920.
155. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891-1898.
156. Heriot WJ, Henkind P, Belhorn RW, Burns MS. Choroidal neovascularization can digest Bruch's membrane: a prior break is not essential. Ophthalmology. 1984;91:1603-1608.
157. 2+ mobilization, stimulation of respiratory burst and enzyme secretion. Biochem Biophys Res Commun. 1986;141:92-98.
158. Faury G, Ristori MT, Verdetti J, Jacob MP, Robert L. Effect of elastin peptides on vascular tone. J Vasc Res. 1995;32:112-119.
159. Van der Schaft T, Mooy CM, de Bruijn WC, de Jong PT. Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol. 1993;77:657-661.
160. Streilein JW, Ma N, Wenkel H, Ng TF, Zamiri P. Immunobiology and privilege of neuronal retinal and pigment epithelium transplants. Vision Res. 2002;42:487-495.
161. Penfold P, Provis J, Furby J, Gatenby P, Billson F. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1990;228:270-274.
162. Guerne D, Tso M, Edward D, Ripps H. Antiretinal antibodies in serum of patients with age-related macular degeneration. Ophthalmology. 1991;98:602-607.
163. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
164. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:11830-11835.
165. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985;103:708-711.
166. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
167. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJC, Provis JM. Triamcinolone acetonide modulates the permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121:1-9.
168. Elner SG, Pavilack MA, Todd RF, et al. Modulation and function of intracellular adhesion molecule-1 (CD54) on human retinal epithelial cells. Lab Invest. 1992;66:200-211.
169. Duguid IG, Boyd AW, Mandel TE. Adhesion molecules are expressed in the human retina and choroid. Curr Eye Res. 1992;11:153-159.
170. Feeney-Burns L, Ellersieck MR. Age-related changes in the ultrastructure of Bruch's membrane. Am J Ophthalmol. 1985;100:686-697.
171. Rungger-Brandle E, Englert J, Leuenberger PM. Exocytic clearing of degraded membrane material from pigment epithelial cells in frog retina. Invest Ophthalmol Vis Sci. 1987;28:2026-2037.
172. Burns RP, Feeney-Burns L. Clinicomorphologic correlations of drusen and Bruch's membrane. Trans Am Ophthalmol Soc. 1980;78:206-223.
173. Sarks JP, Sarks SH, Killingsworth MC. Evolution of soft drusen in age-related macular degeneration. Eye. 1994;8:269-283.
174. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina. 1994;14:130-142.
175. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol. 1999;44:1-29.
176. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-846.
177. Haimovici R, Gantz DL, Rumelt S, Freddo TF, Small DM. The lipid composition of drusen, Bruch's membrane, and sclera by hot stage polarizing light microscopy. Invest Ophthalmol Vis Sci. 2001;42:1592-1599.
178. Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP. Early drusen formation in the normal and aging eye and their relation to age-related maculopathy: a clinicopathological study. Br J Ophthalmol. 1999;83:358-368.
179. Sarks SH. Drusen patterns predisposing to geographic atrophy of the retinal pigment epithelium. Aust J Ophthalmol. 1982;10:91-97.
180. Mullins RF, Johnson LV, Anderson DH, Hageman GS. Characterization of drusen-associated glycoconjugates. Ophthalmology. 1997;104:288-294.
181. Marmorstein AD, Marmorstein LY, Sakaguchi H, Hollyfield JG. Spectral profiling of autofluorescence associated with lipofuscin, Bruch's membrane, and sub-RPE deposits in normal and AMD eyes. Invest Ophthalmol Vis Sci. 2002;43:2435-2441.
182. Malek G, Li C-M, Guidry C, Medeiros NE, Curcio CA. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol. 2003;162:413-425.
183. Friedman E, Smith TR, Kuwabara T. Senile choroidal vascular patterns and drusen. Arch Ophthalmol. 1963;69:220-330.
184. Tso MOM. Pathogenetic features of aging macular degeneration. Ophthalmology. 1985;92:628-635.
185. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001;39:380-384.
186. Leu ST, Batni S, Radeke MJ, Johnson LV, Anderson DH, Clegg DO. Drusen are cold spots for proteolysis: expression of matrix metalloproteinases and
187. Farboud B, Aotaki-Keen A, Miyata T, Hlelmeland LM, Handa JT. Development of a polyclonal antibody with broad epitope specificity for advanced glycation end products and localization of these epitopes in Bruch's membrane of the ageing eye. Mol Vis. 1999;5:11.
188. Pauleikhoff D, Spital G, Radermacher M, Brumm GA, Lommatzsch A, Bird AC. A fluorescein and indocyanine green angiographic study of choriocapillaris in age-related macular disease. Arch Ophthalmol. 1999;117:1353-1358.
189. Chen JC, Fitzke RW, Pauleikhoff D, Bird AC. Functional loss in age-related Bruch's membrane change with choroidal perfusion defect. Invest Ophthalmol Vis Sci. 1992;33:334-340.
190. Remulla JF, Gaudio AR, Miller S, Sandberg MA. Foveal electroretinograms and choroidal perfusion characteristics in fellow eyes of patients with unilateral neovascular age-related macular degeneration. Br J Ophthalmol. 1995;79:558-561.
191. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
192. Frank RN. Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. Ophthalmic Res. 1997;29:341-353.
193. Kvanta A, Algvere P, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
194. Sarks JP, Sarks SH, Killingsworth MO. Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye. 1997;11:515-522.
195. Nasir M, Sugino I, Zarbin MA. Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration. Br J Ophthalmol. 1997;81:481-489.
196. McLeod DS, Lutty GA. High-resolution histologic analysis of the human choroidal vasculature. Invest Ophthalmol Vis Sci. 1994;35:3799-3811.
197. Chen SJ, Cheng CY, Lee AF, et al. Pulsatile ocular blood flow in asymmetric exudative age-related macular degeneration. Br J Ophthalmol. 2001;85:1411-1415.
198. Kaplan HJ, Leibole MA, Tezel T, Ferguson TA. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat Med. 1999;5:292-297.
199. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115-2121.
200. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154-162.
201. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularization. Br J Ophthalmol. 1996;80:363-366.
202. Lip P-L, Blann AD, Hope-Ross M, Gibson JM, Lip GYH. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology. 2001;108:705-710.
203. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
204. Seo M-S, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol. 1999;154:1743-1753.
205. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001;158:1161-1172.
206. Spilsbury C, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to development of choroidal neovascularization. Am J Pathol. 2000;157:135-144.
207. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci. 1989;30:1700-1707.
208. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
209. Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol. 2001;189:323-333.
210. Mori K, Gehlbach P, Yamamoto S, et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:1994-2000.
211. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2002;43:2428-2434.
212. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 1995;376:70-74.
213. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
214. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48-50.
215. Hangai M, Murata T, Miyawaki N, et al. Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:1617-1625.
216. Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1912-1920.
217. Oh H, Takagi H, Suzuma K, Otani A, Honda Y. Vascular endothelial growth factor (VEGF) and hypoxia regulate angiopoietin2 expression in retinal vascular endothelial cells. J Biol Chem. 1999;274:15732-15739.
218. Ahmed J, Braun RD, Dunn RJ, Linsenmeier RA. Oxygen distribution in the macaque retina. Invest Ophthalmol Vis Sci. 1993;34:516-521.
219. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis. 1999;5:34-38.
220. Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factor secretion by retinal pigmented epithelial cells. J Cell Biochem. 1999;74:135-143.
221. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.
222. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233-240
223. Murata T, He S, Hangai M, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:2309-2317.
224. Sipos E, Tamargo R, Weingart J, Brem H. Inhibition of tumor angiogenesis. Ann N Y Acad Sci. 1994;732:263-272.
225. Taraboletti G, Garofalo A, Belotti D. Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst. 1995;87:293-298.
226. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998;39:2194-2200.
227. Kvanta A, Shen WY, Sarman S, Seregard S, Steen B, Rakoczy E. Matrix metalloproteinases (MMP) expression in experimental choroidal neovascularization. Curr Eye Res. 2000;21:684-690.
228. Grunwald J, Hariprasad S, DuPont J, et al. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1998;39:385-390.
229. Ciulla TA, Harris A, Chung HS, et al. Color Doppler imaging reveals reduced ocular blood flow velocities in nonexudative age-related macular degeneration. Am J Ophthalmol. 1999;128:75-80.
230. Ciulla TA, Harris A, Kagemann L, et al. Choroidal perfusion perturbations in non-neovascular age-related macular degeneration. Br J Ophthalmol. 2002;86:209-213.
231. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye. 1988;2:552-577.
232. Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis. 1999;5:25-30
233. Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42:1051-1056.
234. Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973;90:206-217.
235. Schatz H, McDonald HR. Atrophic macular degeneration: rate of spread of geographic atrophy and visual loss. Ophthalmology. 1989;96:1541-1551.
236. Welter JJ, Delori F, Dorey CK. Central sparing in annular macular degeneration. Am J Ophthalmol. 1988;106:286-292.
237. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins B, Applegate CA. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. Ophthalmology. 1999;106:910-919.
238. Yates JRW, Moore AT. Genetic susceptibility to age-related macular degeneration. J Med Genet. 2000;37:83-87.
239. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997;123:199-206.
240. Hammond CCJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector T. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology. 2002;109:730-736.
241. Stone EM, Sheffield, VC, Hageman GS. Molecular genetics of age-related macular degeneration. Hum Mol Genet. 2001;10:2285-2292.
242. Kuntz CA, Jacobson SG, Cideciyan AV, et al. Subretinal pigment epithelial deposits in a dominant late-onset retinal degeneration. Invest Ophthalmol Vis Sci. 1996;37:1772-1782.
243. Piguet B, Heon E, Munier FL, et al. Full characterization of the maculopathy associated with an Arg-172-Trp mutation in the RDS/peripherin gene. Ophthalmic Genet. 1996;17:175-186.
244. Stone EM, Lotery AJ, Munier FL, et al. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet. 1999;22:199-202.
245. Allikmets R, Shroyer NF, Singh N, et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science. 1997;277:1765-1766.
246. Stone EM, Webster AR, Vandenburgh K, et al. Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration. Nat Genet. 1998;20:328-329.
247. De la Paz MA, Pericak-Vance MA, Lennon F, Hames JL, Seddon JM. Exclusion of TIMP-3 as a candidate locus in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1997;38:1060-1064.
248. Fellbor U, Doepner D, Schneider U, Zrenner E, Weber BH. Evaluation of the gene encoding the tissue inhibitor of metalloproteinases-3 in various maculopathies. Invest Ophthalmol Vis Sci. 1997;38:1054-1059.
249. Starita C, Hussain AA, Marshall J. Decreasing hydraulic conductivity of Bruch's membrane: relevance to photoreceptor survival and lipofuscinoses. Am J Med Genet. 1995;57:235-237.
250. Bohr VA, Dianov G, Balajee A, May A, Orren DK. DNA repair and transcription in human premature aging disorders. J Investig Dermatol Symp Proc. 1998;3:11-13.
251. Robert L, Peterszegi G. Aging and matrix biology. Pathol Biol (Paris). 1998;46:491-495.
252. Munch G, Schinzel R, Loske C, et al. Alzheimer's disease: synergistic effects of glucose deficit, oxidative stress and advanced glycation end products. J Neurat Transm. 1998;105:439-461.
253. Ambati J, Anand A, Fernandez S, et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med. 2003;9:1390-1397.
254. Ye SQ, Usher DC, Zhang LQ. Gene expression profiling of human diseases by serial analysis of gene expression. J Biomed Sci. 2002;9:384-394.
255. Lanchoney DM, Maguire MG, Fine SL. A model of the incidence and consequences of choroidal neovascularization secondary to age-related macular degeneration: comparative effects of current treatment and potential prophylaxis on visual outcomes in high-risk patients. Arch Ophthalmol. 1998;116:1045-1052.
256. Nelson KC, Carlson J, Newman ML, et al. Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40:1927-1935.
257. Benson AB III, Olopade OI, Ratain MJ, et al. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clin Cancer Res. 2000;6:3870-3877.
258. Ahir A, Guo L, Hussain AA, Marshall J. Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci. 2002;43:458-465.
259. Sundelin SP, Nilsson SE. Lipofuscin formation in retinal pigment epithelial cells is reduced by antioxidants. Free Radic Biol Med. 2001;31:217-225.
260. Dylewski DP, Nandy S, Nandy K. Effects of centrophenoxine on lipofuscin in the retinal pigment epithelium of old mice. Neurobiol Aging. 1983;4:89-95.
261. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol: an open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther. 2001;12:2029-2032.
262. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2003;110:979-986.
263. Ranson NT, Danis RP, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol. 2002;86:527-529.
264. Takahashi T, Nakamura T, Hayashi A, et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am J Ophthalmol. 2000;130:774-781.
265. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
266. Hangai M, Moon YS, Kitaya N, et al. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum Gene Ther. 2001;12:1311-1321.
267. Zarbin MA, Sugino IK, Castellarin A. RPE transplantation for age-related macular degeneration. In: Fine S, Berger J, Maguire M, eds. Age-Related Macular Degeneration. Philadelphia, Pa: Mosby-Year Book Inc; 1999:363-382.
268. Benner JD, Sunness JS, Ziegler MD, Soltanian J. Limited macular translocation for atrophic maculopathy. Arch Ophthalmol. 2002;120:586-591.
269. Del Priore LV, Kaplan HJ, Tezel TH, Hayashi N, Berger AS, Green WR. Retinal pigment epithelial cell transplantation after subfoveal membranectomy in age-related macular degeneration: clinicopathologic correlation. Am J Ophthalmol. 2001;131:472-480.
270. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998;39:592-602.